Clinical operations
What the Bepirovirsen Trials Show About Stopping Hepatitis B Treatment
See who qualifies for FDA-approved bepirovirsen, how B-Well measured functional cure, and what trial teams can do to protect off-treatment follow-up.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
Some adults with chronic hepatitis B can maintain viral control after stopping all hepatitis B treatment. On October 20, 2026, the FDA approved Hibsago (bepirovirsen) in combination with an existing oral antiviral for adults without cirrhosis who have received that therapy for at least six months, have suppressed hepatitis B virus (HBV) DNA, and have a hepatitis B surface antigen (HBsAg) level of 3,000 IU/mL or less on an FDA-authorized test. Bepirovirsen is an antisense oligonucleotide that targets viral RNA and reduces production of viral proteins, including surface antigen. [1, 2]
GSK’s B-Well 1 and 2 trials randomized 1,838 adults. The efficacy analysis included 1,834 who received at least one dose. Both groups continued their oral antiviral while receiving bepirovirsen or placebo for 24 weeks. The oral antiviral continued for another 24 weeks, and only participants who met prespecified criteria stopped it at week 48. At week 72, 233 of 1,220 participants receiving bepirovirsen (19%) met the functional cure endpoint, compared with 0 of 614 receiving placebo. The endpoint required HBV DNA below the level the test could quantify and no detectable HBsAg 24 weeks after all treatment stopped, without rescue medication. [2, 3]
The November 7 program at The Liver Meeting in Denver included B-Well end-of-study results and an analysis of whether week-12 surface antigen levels could predict response. The FDA label reports that 211 of the 233 week-72 responders (91%) remained in response at week 96. That figure describes durability among initial responders. The longer-term effect on liver cancer risk remains an open question. [2, 7]
During the treatment period, grade 3 or higher adverse events occurred in 16% of bepirovirsen recipients and 3% of placebo recipients. The label carries a boxed warning for on-treatment liver flares and thrombocytopenia (low platelet counts). [2, 3]
What this means for trial teams
Plan the off-treatment period before the first participant stops therapy. In a trial using this type of endpoint, define who checks when a sample is due, who confirms the lab received it, and who alerts the investigator if a draw is missed or the result requires action. A clinical research associate can verify the dates, lab reports and escalation records. Treatment decisions remain with the investigator.
Look for patterns across sites. If several sites miss the same follow-up window, check whether the issue is visit scheduling, travel, language access, or a shared laboratory workflow. Track the share of expected off-treatment draws collected on time and the time from an actionable result to investigator review. Break those measures down by site and participant group so the study team can see whose data are missing.
Track what happens after a positive screen. WHO estimated that 240 million people lived with chronic hepatitis B in 2024, and fewer than 5% were receiving treatment. Chronic infection can progress to cirrhosis and primary liver cancer. CDC recommends that adults be screened at least once with a three-test panel. ASCO also recommends HBV testing before or at the start of systemic cancer therapy so teams can assess reactivation risk. A positive result needs a named owner and a way to confirm that the patient received follow-up. [4–6]
Sources
- FDA • Hibsago approval announcement, October 20, 2026
- FDA • Hibsago prescribing information, including safety and B-Well results
- New England Journal of Medicine • B-Well 1 and 2 Phase 3 results
- WHO • Global Hepatitis Report 2026
- CDC • Clinical testing and diagnosis for hepatitis B
- ASCO • Hepatitis B screening and management before cancer therapy
- AASLD • Functional cure and novel therapeutics at The Liver Meeting 2026
- GSK • Hepatitis B explained
- Lampgen Clinical Insights • Clinical trial participation burden and patient access